QEL-002 / Quell Therap, AstraZeneca - LARVOL DELTA

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases (GlobeNewswire) - "Quell Therapeutics Ltd...announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications....Under the terms of the agreement, Quell’s proprietary toolbox of Treg cell engineering modules, including its Foxp3 Phenotype Lock, will be leveraged to develop autologous multi-modular Treg cell therapy candidates for Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD)."

Licensing / partnership • Immunology • Inflammatory Bowel Disease